<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>ex99-2.htm
<TEXT>
<!doctype html>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><b>Exhibit 99.2</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="ex99-2_001.jpg" alt=""></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Cuprina Holdings (Cayman) Limited Announces Closing
of Initial Public Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>SINGAPORE, April 11, 2025</b>
&ndash; <b>Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR)</b> (&#8220;<b>CUPR</b>&#8221; or &#8220;the <b>Company</b>&#8221;), a biomedical
and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds as well
as cosmeceuticals for the health and beauty sector, today announced <font style="background-color: white">the closing of its previously
announced initial public offering of </font>an aggregate 3,000,000 Class A Ordinary Shares (<b>&#8220;the Offering</b>&#8221;) at a price
of $4.00 per share (<b>&#8220;the Offering Price</b>&#8221;) to the public<font style="background-color: white">, for a total of $12.0
million of gross proceeds to the Company, before deducting underwriting discounts and offering expenses. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company intends to use
net proceeds from the Offering for expansion into new markets, R&amp;D activities to expand its product portfolio, research and development
activities, building brand awareness, investment in equipment and infrastructure, and working capital and general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares began trading on the NASDAQ Stock Market
LLC on April 10, 2025, under the symbol &#8220;CUPR&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">R. F. Lafferty &amp; Co., Inc. (&#8220;<b>R. F. Lafferty</b>&#8221;)<font style="background-color: white">,</font>
acted as the sole book-running manager for the Offering. Loeb &amp; Loeb LLP, Lee &amp; Lee, Harney Westwood &amp; Riegels Singapore LLP
are acting as U.S., Singapore and Cayman Islands legal counsels to the Company, respectively, and Winston &amp; Strawn LLP is acting as
U.S. legal counsel to R. F. Lafferty for the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#8220;We are gratified to
close this Offering,&#8221; said Cuprina chief executive David Quek. &#8220;Our chronic wound care products, we believe, are poised to
gain escalating market acceptance due primarily to the steadily aging global population and concurrent rise in diabetes, obesity, cardiovascular
ailments and peripheral vascular diseases, all of which are associated with chronic wounds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#8220;Our mission is to
treat these wounds with sustainable, nature-derived raw materials containing bioactives widely demonstrated in clinical studies to achieve
superior clinical outcomes and reduce costs of care compared to most traditional treatment modalities.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Offering is being conducted pursuant to the Company&#8217;s
registration statement on Form F-1 (File No. 333-283643), as amended, previously filed with and subsequently declared effective by the
U.S. Securities and Exchange Commission (&#8220;<b>SEC</b>&#8221;) on March 31, 2025. The Offering is being made only by means of a prospectus,
forming part of the registration statement. Copies of the final prospectus related to the Offering may be obtained, when available, from
R. F. Lafferty &amp; Co., Inc., 40 Wall Street, 27th Floor, New York, NY 10005; (212) 293-9090, or by email at offerings@rflafferty.com.
In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC&#8217;s website at www.sec.gov<font style="background-color: white">.
</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before you invest, you should read the prospectus
and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press
release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to
buy these securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption
from registration, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>About Cuprina Holdings (Cayman) Limited</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a Singapore-based biomedical and biotechnology
company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well
as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived
from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information,
please visit https:// www.cuprina.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain statements contained in this press release
about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute
&#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words &#8220;anticipate,&#8221;
&#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221;
&#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221;
&#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the
public offering on the anticipated terms or at all, and other factors discussed in the &#8220;Risk Factors&#8221; section of the preliminary
prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking
statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and
Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of
new information, future events or otherwise, except as required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Cuprina Holdings (Cayman) Limited Investor Contact</b></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0">Investor Relations</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">c/o Blk 1090 Lower Delta Road #06-08</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Singapore 169201</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">+65 8512 7275</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Email: ir@cuprina.com.sg</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Investor Relations Inquiries:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Skyline Corporate Communications Group, LLC</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Scott Powell, President</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">1177 Avenue of the Americas, 5<sup>th</sup> Floor</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">New York, New York 10036</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Office: (646) 893-5835</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Email: info@skylineccg.com</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>
<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
